Xinqiao Hospital Of Chongqing

This early-phase trial tested a new treatment for people with advanced nasopharyngeal cancer that is linked to the Epstein-Barr virus. The treatment uses specially engineered immune cells (TCR-T cells) that can recognize and attack the virus on cancer cells, plus they release a c…

This study tested a new treatment called Anti-ALPP CAR-T cells in 5 people with advanced solid tumors that had not responded to standard therapies. The treatment uses a patient's own immune cells, modified to find and attack cancer cells that have a specific marker (ALPP). The ma…

This trial tested a new treatment for a type of head and neck cancer linked to the Epstein-Barr virus. Researchers took patients' own immune cells, engineered them to recognize and attack the virus on cancer cells, and also added a feature to block a common cancer defense. The st…

This early-stage trial tested a new treatment for people with HPV-positive head and neck or cervical cancer that has spread or come back. The therapy uses a patient's own immune cells, engineered to recognize and attack HPV-infected cancer cells. Some cells were also modified to …

This early-phase study tested a new type of cell therapy (CAR-T cells) designed to attack tumors that have a protein called ALPP. Five adults with advanced solid tumors that had no standard treatment options received the therapy. The main goals were to check safety and see if the…